Last edition
News about
Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations
The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.
LB Pharmaceuticals Raises 285 Million USD in Biotech IPO, Valued at Over 300 Million
LB Pharmaceuticals has raised 285 million USD in its initial public offering in the United States, the biotechnology company has confirmed, marking the first major biotech IPO since February. The New York-based firm sold 19 million shares at 15 USD apiece, pricing the offering within its earlier indicated range of 14 to 16 USD per share.
Merck Shuts Down London Drug Discovery Centre, Moves R&D Focus to US
Merck has announced that it will discontinue its drug discovery operations in London, citing an increasingly challenging business environment in the UK. The company has abandoned plans to occupy the Belgrove House site at King’s Cross—which had been scheduled to open in 2027—and will relocate research activities primarily to existing sites in the USA.
Hoggan Scientific Moves Medical Dynamometers to USB-C Charging
Hoggan Scientific, LLC is transitioning its digital dynamometers and force gauges to USB-C charging.
Bayer Launches Bayer Co.Lab AdVenture Platform in China
Bayer launches Co.Lab AdVenture to connect biotech startups with global VCs, accelerating early-stage innovation through its lifesciences incubator network.
Sanofi Drug Earns Fast Track Status for Wet AMD in US
Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.
Pfizer, Novartis, Roche Lead Net-Zero Pharma Supply Chain Transition
Europe currently dominates the global net-zero pharma supply chain market supported by strict climate regulations, while Asia-Pacific is the fastest-growing region, spurred by new government-led sustainability policies.
RION Forms INTENT Biologics to Develop Clinical Exosome-Based Therapies
With the launch of INTENT Biologics, RION targets global impact in inflammation care; Suneet Varma named CEO to lead the charge.
Dr. Reddy's Acquires STUGERON Brand from Johnson & Johnson to Strengthen CNS Portfolio
Dr. Reddy’s, a global pharmaceutical company, has announced the completion of a definitive agreement with Johnson & Johnson to acquire STUGERON and its associated brands, STUGERON FORTE and STUGERON PLUS, across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East and Africa (EMEA) regions.
GTCR to Acquire Zentiva in 4.8 Billion USD Private Equity Buy-out
Private equity firm GTCR has entered into an agreement to acquire Zentiva, a pharmaceutical company headquartered in Europe, for approximately 4.8 billion USD (roughly 4.4 billion EURO based on current exchange rates).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy